Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03797495Recruiting

Study of Individuals Affected With Hypoplasminogenemia

Role: collaborator

NCT02460458Completed

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

Role: lead

NCT01064284Phase 4Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers

Role: lead

All 3 trials loaded